Market Research Logo

Gastric Ulcers - Pipeline Review, H2 2016

Gastric Ulcers - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Gastric Ulcers - Pipeline Review, H2 2016’, provides an overview of the Gastric Ulcers pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gastric Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastric Ulcers and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Gastric Ulcers
    • The report reviews pipeline therapeutics for Gastric Ulcers by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Gastric Ulcers therapeutics and enlists all their major and minor projects
    • The report assesses Gastric Ulcers therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Gastric Ulcers
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Gastric Ulcers
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Gastric Ulcers pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Gastric Ulcers Overview
    Therapeutics Development
    Pipeline Products for Gastric Ulcers - Overview
    Gastric Ulcers - Therapeutics under Development by Companies
    Gastric Ulcers - Pipeline Products Glance
    Clinical Stage Products
    Early Stage Products
    Gastric Ulcers - Products under Development by Companies
    Gastric Ulcers - Companies Involved in Therapeutics Development
    Ache Laboratorios Farmaceuticos S/A
    Astellas Pharma Inc.
    ChoDang Pharm Co., Ltd.
    Kukje Pharmaceutical Industry Co., Ltd.
    XuanZhu Pharma Co., Ltd.
    Gastric Ulcers - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    (ecabet + ranitidine) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    anaprazole sodium - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ASP-6537 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KJ-14001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PDI-39 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PMKS-005 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Gastric Ulcers - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gastric Ulcers - Dormant Projects
    Gastric Ulcers - Discontinued Products
    Gastric Ulcers - Product Development Milestones
    Featured News & Press Releases
    Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies
    Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck
    Jan 07, 2010: AstraZeneca Reaches Agreements with Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations
    Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy
    Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.
    Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)
    Jun 01, 2007: AstraZeneca’s Prilosec Patents Upheld By Court
    Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court
    Aug 08, 2003: Astrazeneca to Seek Triple Damages in Patent Infringement Lawsuit Against Mylan Pharmaceuticals
    Oct 23, 2001: Prilosec US litigation
    May 02, 2001: Astrazeneca Receives Six Months' Market Exclusivity for Prilosec
    May 02, 2001: Court Denies Generic's Application for Summary Judgement on Prilosec Patent
    Apr 23, 2001: Astrazeneca Files Lawsuit Against Apotex Corporation and Torpharm for Patent Infringement
    Dec 19, 2000: Astrazeneca Wins Losec Patent Litigation in Canada
    Oct 20, 2000: Joint FDA Advisory Committee Confirms OTC Prilosec (Omeprazole) Safety and Efficacy
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Gastric Ulcers, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Gastric Ulcers - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016
    Gastric Ulcers - Pipeline by Astellas Pharma Inc., H2 2016
    Gastric Ulcers - Pipeline by ChoDang Pharm Co., Ltd., H2 2016
    Gastric Ulcers - Pipeline by Kukje Pharmaceutical Industry Co., Ltd., H2 2016
    Gastric Ulcers - Pipeline by XuanZhu Pharma Co., Ltd., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Gastric Ulcers - Dormant Projects, H2 2016
    Gastric Ulcers - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Gastric Ulcers, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Targets, H2 2016
    Number of Products by Stage and Targets, H2 2016
    Number of Products by Mechanism of Actions, H2 2016
    Number of Products by Stage and Mechanism of Actions, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report